Author

Francesca Alvarez Calderon

Boston Children's HospitalORCID 0000-0001-5620-8431Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

Marlana Winschel· 3 shared Ulrike GerdemanniD· 3 shared Elisa Rojas PalatoiD· 2 shared Katherine A. MichaelisiD· 2 shared Kayleigh Ingersoll OmdahliD· 2 shared Leslie S. KeaniD· 2 shared Lorenzo S CagniniD· 2 shared Victor TkacheviD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Marlana Winschel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyBlood Immunology & Cellular TherapyPeer-reviewedApr 20, 2026

Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies

Holly Wobma, Francesca Alvarez Calderon, Jiayi Dong…·Leslie S. Kean

This study edits Cyclophilin A's C-terminus using CRISPR/Cas9 to create cell therapies resistant to cyclosporine and voclosporin, preserving function in immune suppression settings.

DOI 10.1016/j.bict.2026.100054

mousegenetic perturbation / CRISPR

𝕏 PostBluesky

ImmunologybioRxivPreprintSep 17, 2025

PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model

Francesca Alvarez Calderon, Ryan A. Fleming, Marlana Winschel…·Ulrike Gerdemann

DOI 10.1101/2025.09.17.676426

non-human primatebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 1, 2025

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma

Nina Weichert‐Leahey, Alla Berezovskaya, Mark W. Zimmerman…·Alfred Thomas Look

This study shows that inhibiting KAT6A/B with PF-9363 enhances retinoid efficacy and improves GD2-targeted immunotherapy in neuroblastoma.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky